177Lu-DOTATATE在肽受体放射性核素治疗期间的体内不稳定性
该研究对6例接受177Lu-DOTATATE治疗的神经内分泌肿瘤患者,在注射后0.5、4、24和96小时采血,用高效液相色谱分析代谢稳定性。结论认为其体内稳定性远低于既往假设,注射后24小时血浆放射性大部分已为177Lu标记代谢物。
要点
- 6例神经内分泌肿瘤患者注射177Lu-DOTATATE后0.5、4、24、96小时采血分析。
- 注射后24小时血浆放射性大部分已为177Lu标记代谢物。
核心结论
- 177Lu-DOTATATE的体内稳定性远低于既往假设,注射后24小时血浆放射性大部分已为177Lu标记代谢物。
研究设计与样本
- 研究纳入6例接受177Lu-DOTATATE治疗的神经内分泌肿瘤患者,在注射后0.5、4、24和96小时采集血样,采用高效液相色谱分析代谢稳定性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Peptide receptor radiotherapy using 177Lu-labeled somatostatin ligand analogs is a well-established treatment for neuroendocrine tumors, with 177Lu-DOTATATE having acquired marketing authorization in Europe and the United States. The investigation of the pharmacokinetics of these radiopharmaceuticals in vivo in humans is crucial for personalized treatment management and understanding of treatment effects. Such an investigation requires input data on the in vivo stability of the radiopharmaceuticals in blood and plasma. The work presented here is devoted to the investigation of the in vivo stability of 177Lu-DOTATATE in humans affected by neuroendocrine tumors. Methods: Blood samples of 6 patients undergoing 177Lu-DOTATATE were taken at 0.5, 4, 24, and 96 h after injection. Analysis of metabolic stability was performed using high-performance liquid chromatography. Results: A fast metabolism of the radiopharmaceutical was observed, with the fraction of intact 177Lu-DOTATATE in plasma decreasing rapidly to 23% ± 5% (mean ± SD) at 24 h and 1.7% ±0. 9% at 96 h after injection. Conclusion: The in vivo stability of 177Lu-DOTATATE is much lower than previously assumed, with the major part of radioactivity in plasma consisting of 177Lu-labeled metabolites already at 24 h after injection.
引用
- Lubberink M, Wilking H, Öst A, et al. In Vivo Instability of 177Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020. PMID: 32005767. doi:10.2967/jnumed.119.237818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。